A5101588286- Alzheimer's disease research and treatments
- Neuroscience and Neuropharmacology Research
- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Neuroinflammation and Neurodegeneration Mechanisms
- Cellular transport and secretion
- S100 Proteins and Annexins
- Functional Brain Connectivity Studies
- Tryptophan and brain disorders
- Computational Drug Discovery Methods
Karolinska Institutet
2023-2025
Universidade do Porto
2023
Abstract BACKGROUND Despite significant astrocytic involvement in Parkinson's disease (PD), the knowledge regarding role of reactive astrogliosis is still at surface level; largely due to lack specific biomarkers track these processes. Novel astroglial PET‐tracers BU99008 and Deprenyl, hold immense potential for visualizing PD. However, they have not been thoroughly investigated METHODS We employed a multi‐marker approach performed vitro radioligand binding autoradiography studies with 3...
Abstract INTRODUCTION Progressive supranuclear palsy (PSP) is a devastating 4R tauopathy affecting motor functions and often misdiagnosed/underdiagnosed due to lack of specific biomarkers. Synaptic loss an eminent feature tauopathies including PSP. Novel synaptic positron emission tomography tracer UCB‐J holds great potential for early diagnosis; however, there substantial knowledge gap in terms the mechanism extent nature METHODS Here, we report in‐depth post mortem validation mechanistic...
Abstract Background Synaptic loss is an eminent feature of tauopathies. The recently developed novel SV2A PET‐tracer UCB‐J has shown great promise in tracking synaptic However, there have been discrepancies between the vivo findings and a lack mechanistic insight. Many these studies indicated potential correlations tau deposition, atrophy, cognitive‐impairment, binding. Hence, we found it utmost relevance to perform extensive pre‐clinical validation tauopathic brains gain deeper...
Abstract Background The knowledge regarding the role of reactive astrogliosis in Parkinson’s disease (PD) is still at surface level, however, a few vivo PET studies have speculated that could be an early event PD pathology. Moreover, direct link between a‐synuclein pathology and astrocytes has been also shown, where play key propagation by shuttling neurons astrocytes. imaging field advancing very fast different astrocytic‐tracers are now available, such as 11C‐Deprenyl (DED) (targeting...
Abstract Background The knowledge regarding the role of reactive astrogliosis in Parkinson’s disease (PD) is still at surface level, however, a few vivo PET studies have speculated that could be an early event PD pathology. Moreover, direct link between α‐synuclein pathology and astrocytes has been also shown, where play key propagation by shuttling neurons astrocytes. imaging field advancing very fast different astrocytic‐tracers are now available, such as 11 C‐Deprenyl (DED) (targeting...